(3R)-1,2,3,4-四氢-3-异喹啉甲胺 | 1187932-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: (3R)-1,2,3,4-四氢-3-异喹啉甲胺
• 英文名称: (R)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanamine
• 英文别名: [(3R)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanamine
• CAS: 1187932-41-7
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.23
• InChiKey: QQDYNQIMTRERLH-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
  申请人：Raynham Tony Michael

  公开号：US20090247519A1

  公开（公告）日：2009-10-01

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些氨基乙基氨基芳基（AEAA）化合物，该化合物在抑制蛋白激酶D（PKD）（例如，PKD1、PKD2、PKD3）方面起作用。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制PKD，并用于治疗由PKD介导的疾病和症状，通过抑制PKD而改善的疾病和症状等，包括增殖性疾病如癌症等。
• [EN] AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE<br/>[FR] AMINO-ÉTHYL-AMINO-ARYLES (AEAA) ET LEURS APPLICATIONS
  申请人：CANCER REC TECH LTD

  公开号：WO2007125331A2

  公开（公告）日：2007-11-08

  [EN] The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
  [FR] La présente invention concerne de façon générale le domaine des composés thérapeutiques, et plus spécifiquement certains amino-éthyl-amino-aryles (AEAA) qui, entre autres, inhibent une protéine kinase D (PKD) (par exemple PKD1, PKD2, PKD3). La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés et l'emploi de tels composés et compositions, à la fois in vitro et in vivo, pour inhiber PKD, ainsi que dans le traitement de maladies et d'états pathologiques faisant intervenir PKD et qui sont soulagés par l'inhibition de PKD, entre autres, y compris des états pathologiques prolifératifs tels que les cancers, etc.